These findings indicate that TRPV4 deletion alleviates the effects of isoproterenol infusion on cardiac hypertrophy and especially on cardiac fibrosis, thereby providing protection against the development of adverse cardiac remodeling and inducible arrhythmias. This evidence concerns the gene TRPV4 and cardiac arrhythmia.